Schrödinger, Inc. (SDGR) achieved $128 million in revenue for Q4 2025, marking a 42% increase from the same period the prior year, driven by a pivot to a licensing-based revenue structure. The transition has strengthened financial performance and attracted investor interest in software-enabled drug discovery platforms.
- Schrödinger, Inc. (SDGR) reported $128 million in Q4 2025 revenue, a 42% YoY increase.
- Licensing revenue now constitutes 73% of total revenue, up from 48% in Q4 2024.
- Licensing income rose 61% YoY, contributing to a 31% gross margin improvement.
- SDGR shares surged 18% post-earnings, outperforming the XLV ETF's 4.2% gain.
- Six new pharma licensing deals were signed in 2025, including one with a top-10 global pharmaceutical company.
- Management targets $500 million in annualized revenue by 2027, with licensing exceeding 80% of total sales.
Schrödinger, Inc. (SDGR) reported a significant acceleration in revenue growth during the fourth quarter of 2025, posting $128 million in total revenue, a 42% year-over-year increase. This performance reflects the company's strategic shift toward a licensing model, which now accounts for 73% of total revenue, up from 48% in Q4 2024. The change has enabled more predictable income streams and deeper partnerships with pharmaceutical firms seeking access to Schrödinger’s AI-driven molecular modeling platform. The transition marks a pivotal evolution in the company’s business model, moving beyond service-based contracts to long-term licensing agreements. These agreements include milestone payments and royalty provisions tied to product development and commercialization, enhancing revenue visibility. In Q4 alone, licensing-related income rose by 61%, contributing directly to a 31% improvement in gross margin compared to the prior year. The financial momentum has been mirrored in market sentiment. SDGR shares rose 18% in early trading following the earnings release, outpacing the broader healthcare sector, represented by the XLV ETF, which gained 4.2% over the same period. Analysts note that Schrödinger’s model could serve as a blueprint for other biotech software firms aiming to scale without the capital intensity of traditional R&D pipelines. Investors are also focusing on the company’s expanded partnerships, which now include six new pharmaceutical licensing deals signed in 2025, including a major agreement with a top-10 global pharma company for the development of oncology therapeutics. The success of the licensing model has prompted management to target $500 million in annualized revenue by 2027, with licensing revenues expected to exceed 80% of total sales.